Voyager Therapeutics (NASDAQ:VYGR) is a clinical-stage biotechnology company dedicated to developing and commercializing novel gene therapies for serious neurological diseases. Leveraging its proprietary adeno-associated virus (AAV) vector platform, the company focuses on delivering therapeutic genes directly to affected regions of the central and peripheral nervous systems. Since its founding in 2015 and its headquarters in Cambridge, Massachusetts, Voyager has been committed to addressing disorders with significant unmet medical needs, including movement disorders, neuromuscular diseases and other inherited neurological conditions.
The company’s lead program, VY-AADC, targets Parkinson’s disease by delivering a functional version of the aromatic L-amino acid decarboxylase (AADC) enzyme to the putamen, enhancing dopamine synthesis in patients with advanced motor fluctuations. In parallel, Voyager is advancing VY-FXN for Friedreich’s ataxia, aiming to restore frataxin expression in key regions of the spinal cord and heart, and VY-HTT01 for Huntington’s disease, which uses a microRNA-based approach to reduce mutant huntingtin protein levels in the striatum. Additional preclinical programs seek to expand the company’s pipeline into amyotrophic lateral sclerosis (ALS) and other genetic neuromuscular disorders.
Voyager has established collaborations and strategic partnerships to accelerate its clinical development efforts. These include alliances with leading academic research institutions and global biopharmaceutical companies that provide access to complementary expertise, scale and distribution channels. Through these partnerships, Voyager extends its reach beyond the United States, engaging in research activities and clinical sites across North America and Europe to facilitate patient enrollment and regulatory interactions.
The company was founded by a team of seasoned scientists and industry veterans with deep expertise in gene therapy, virology and neurology. Under the leadership of President and Chief Executive Officer Andrew Allen, Voyager has built a multidisciplinary management team and board of directors with experience spanning drug development, regulatory affairs and commercial strategy. This leadership framework guides the company’s strategic vision as it moves its gene therapy candidates toward regulatory milestones and potential commercialization.
